北京合生基因科技

Hesheng Gene is a clinical-stage biotechnology company headquartered in Beijing that specializes in the development of innovative gene therapies and oncolytic viruses using synthetic biology. The company utilizes its proprietary Gene Circuit platform to engineer genetic programs that enable precise, environment-specific control of therapeutic gene expression, aiming to improve the safety and efficacy of cancer treatments. Its lead candidate, Syn-002, is an oncolytic adenovirus currently in Phase 1/2 clinical trials for the treatment of advanced solid tumors, including liver cancer. Founded by experts from Tsinghua University, Hesheng Gene integrates advanced genetic engineering with viral vector technology to create intelligent medicines for unmet medical needs in oncology.